Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
- Bianca Weinstock-Guttman
- , Steven L. Galetta
- , Gavin Giovannoni
- , Eva Havrdova
- , Michael Hutchinson
- , Ludwig Kappos
- , Paul W. O'Connor
- , J. Theodore Phillips
- , Chris Polman
- , William H. Stuart
- , Frances Lynn
- , Christophe Hotermans
- University of Pennsylvania
- Queen Mary University of London
- Charles University
- University College Dublin
- University of Basel
- University of Toronto
- MS Center at Texas Neurology
- VU University
- MS Center of Atlanta
- Biogen IDEC
Research output: Contribution to journal › Article › peer-review
59
Scopus
citations